Transfer of products from GlaxoSmithKline to Novartis
The following products have been transferred from GlaxoSmithKline to Novartis: Arzenna (ofatumumab); Atriance (nelarabine); Hycamtin (topotecan); Revolade (eltrombopag); Tafinlar (dabrafenib); Tyverb (lapatinib ditosylate); Votrient (pazopanib); Zofran (ondansetron).
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068469
Recommended from Pharmaceutical Press
Commonly known as the Orange Guide, this book is an essential reference for all involved in the manufacture or distribution of medicines in Europe.£82.00Buy now